OncoMatch/Leukemia — Chronic Lymphocytic (CLL)/TP53 / 17p deletion
Leukemia — Chronic Lymphocytic (CLL)TP53 / 17p deletion Clinical Trials
TP53 mutation and/or 17p deletion occur in approximately 5–10% of treatment-naive CLL and up to 40% of relapsed/refractory disease, defining high-risk biology with resistance to chemoimmunotherapy. BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) and venetoclax-based regimens are effective in TP53-altered CLL regardless of deletion status. Trials investigate fixed-duration BTK/BCL2 combination regimens, novel BTK degraders, and CAR-T approaches for TP53-mutant CLL.
Top recruiting TP53 / 17p deletion Leukemia — Chronic Lymphocytic (CLL) trials
Ranked by phase and US site count.
See all trials matched to your profile →A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Loxo Oncology, Inc.
A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL
German CLL Study Group
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Loxo Oncology, Inc.
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Sellas Life Sciences Group
A Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-Naïve, High-Risk CLL/SLL Patients
The First Affiliated Hospital with Nanjing Medical University
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Merck Sharp & Dohme LLC
More TP53 / 17p deletion Leukemia — Chronic Lymphocytic (CLL) trials
Browse other molecular targets with active Leukemia — Chronic Lymphocytic (CLL) trials.